GENOMICS
Expanding the use of genomic sequencing for improved cancer treatment
A recent study concluded that universal molecular testing in stage 4 non-small cell lung cancer is a critical first step in determining the best course of treatment; but adoption of next-generation sequencing (NGS) has been slow. Here, Thermo Fisher Scientific’s Dr Luca Quagliata discusses the issues around widespread introduction of NGS and how oncologists and pathologists can use it to improve outcomes for cancer patients.
Genomic sequencing can have a profound impact on patient outcomes and can hold the key to unlocking a world of more precise, tailored care based on a cancer’s unique genomic profile. A recent study published in JCO
Oncology Practice authored by researchers at MGH, the Sarah Cannon Research Institute, The University of Toledo, UPMB Hillman Cancer Center, Integra Connect and Thermo Fisher Scientific further reinforces the importance of genomic sequencing
for cancer patients prior to the start of treatment. More specifically, the study explored real-world data of patients with non-small cell lung cancer (NSCLC) and concluded that universal molecular testing in stage 4 NSCLC is a critical first step in determining the best course of treatment for patients. The research further points out that prescribing a one-size-fits-all treatment before next- generation sequencing (NGS) results are available may compromise patient outcomes. However, in-house adoption of NGS has been slow and not enough patients are reaping the benefits of genomic sequencing. According to a 2021 US study, less than half of patients who qualify end up getting their tumours sequenced. With patients more likely than ever to be diagnosed with late- stage cancers, there is no time to waste in identifying an optimal treatment.
Next-generation sequencing, once primarily perceived as a research-driven tool for genetic exploration and discovery, has now assumed a prominent role as the rapidly emerging method for molecular profiling in routine clinical diagnostics.
36
In the US, how has genomic sequencing advanced in the last few years? In recent years, the field of genomic sequencing has witnessed substantial advancements that have garnered significant attention from the medical and clinical research communities. Next- generation sequencing, once primarily perceived as a research-driven tool for genetic exploration and discovery, has
FEBRUARY 2024
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
